<DOC>
	<DOCNO>NCT02576574</DOCNO>
	<brief_summary>The purpose study demonstrate superiority regard Overall Survival ( OS ) Progression Free Survival ( PFS ) avelumab versus platinum-based doublet , base Independent Review Committee assessment , Non-small cell lung cancer ( NSCLC ) subject Programmed death ligand 1+ ( PD-L1+ ) tumor</brief_summary>
	<brief_title>Avelumab First-line Non-Small Cell Lung Cancer ( JAVELIN Lung 100 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Male female subject age great equal ( &gt; = ) 18 year With Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 trial entry At least 1 measurable tumor lesion With histologically confirm metastatic recurrent ( Stage IV ) nonsmall cell lung cancer ( NSCLC ) With availability recentlyobtained , formalinfixed , paraffinembedded ( FFPE ) tissue sample contain tumor ( biopsy nonirradiated area preferably within 6 month ) minimum number 10 ( preferably 25 ) unstained tumor slide cut within 1 week , suitable PDL1 expression assessment Subjects must receive treatment systemic lung cancer , estimate life expectancy 12 week Other protocol define criterion could apply Subjects whose disease harbor EGFR mutation , anaplastic lymphoma kinase ( ALK ) rearrangement eligible . Other exclusion criterion include prior therapy antibody drug target T cell coregulatory protein , concurrent anticancer treatment , immunosuppressive agent Known severe hypersensitivity reaction monoclonal antibody ( Grade &gt; = 3 NCI CTCAE v 4.03 ) , history anaphylaxis , uncontrolled asthma ( , 3 feature partially control asthma ) , persist toxicity relate prior therapy Grade &gt; 1 NCICTCAE v 4.03 . Subjects brain metastasis exclude , except meet follow criterion : brain metastasis treat locally clinically stable least 2 week prior randomization , subject must either steroid stable decrease dose &lt; = 10 mg daily prednisone ( equivalent ) , ongoing neurological symptom relate brain localization disease . Other protocol define criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Avelumab</keyword>
	<keyword>MSB0010718C</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>